Inside Therapeutics raises €1M to accelerate its growth, with Aquiti Gestion joining its capital.
Published: 3rd of June 2025
Inside Therapeutics, an innovative French player in nanomedicine, announces the successful closing of a €1 million fundraising round from Aquiti Gestion, via its AVA1 fund, and its historical investors Newfund Heka, Newfund Naeh, and Skalepark, who have renewed their confidence in the company. This strategic operation will enable Inside Therapeutics to accelerate both its commercial and industrial development.
A major player in nanomedicine bioproduction in France
Founded in 2022 by Thomas Guérinier, Matthieu Kerhuel, Audrey Nsamela, Robin Oliveres, and Alexis Peyroles, Inside Therapeutics develops innovative instruments to streamline and scale up the manufacturing of nanomedicines. The company stands out with its nanoparticle synthesis platform, capable of producing a wide range of RNA-LNP-based drug volumes, from research to production. This maximizes the chances of therapeutic commercialization while reducing development time and costs.
After an initial €1.3 million seed funding round in 2024 from Newfund Heka, Newfund Naeh, Skalepark, and Business Angels to support its international expansion, particularly in the U.S. market, Inside Therapeutics has reached several key milestones that consolidate its positioning in the nanomedicine market. Alongside the commercial launch of its first nanoparticle synthesis platform, TAMARA, Inside Tx also signed a strategic distribution partnership with IDEX MPT, a global leader in scientific instrumentation based in the United States.
“Our partnership with IDEX MPT is a decisive milestone for rapidly accelerating our sales in the North American market”
Robin Oliveres, Co-founder, Chief Marketing & Sales Officer
Accelerating market access and expanding a range of innovative instruments
This second fundraising round marks a pivotal moment for Inside Therapeutics, allowing the company to strengthen its commercial development and speed up product industrialization. Aquiti Gestion’s entry into the company’s capital via its AVA1 fund supports this momentum of consolidation and industrial ambition.
“The closing of this funding round symbolically marks the end of a successful creation phase for Inside Tx. With 18 employees, 100% annual revenue growth since our founding in 2022, and a strong footprint in the health sector of Nouvelle-Aquitaine, we’re paving the way to making Inside Therapeutics a key player in nanomedicine manufacturing in France and worldwide.”
Thomas Guerinier – CEO, Inside Therapeutics
“We strongly believe in Inside Tx’s potential to become the reference technology provider for nanomedicine production. We are thrilled to support this dynamic and highly qualified team.”
As part of its development, the Inside Tx team is also continuing its R&D efforts to expand its product line.
“Our next equipment, which will integrate our patented NanoPulse technology, will enable the scalable manufacturing of RNA-based nanomedicines, from small R&D-scale synthesis volumes to large volumes for clinical trials and bioproduction.”
Audrey Nsamela, co-founder and Chief Scientific Officer.
About Aquiti Gestion and its AVA 1 Fund
Founded in 2019 and approved by the AMF (Financial Markets Authority), Aquiti Gestion is a private equity management company. Its team of 20 professionals operates across three sites—Bordeaux, Limoges, and Poitiers—ensuring close regional support for businesses in Nouvelle-Aquitaine. With over €230 million under management, Aquiti Gestion supports companies at every stage: from €10k honor loans for entrepreneurs starting innovative companies to investments of up to €10M for businesses in development or transition phases. Aquiti Gestion is a founding member of the 1Pacte association, which promotes best practices in ESG.
The Aquiti Venture Amorçage 1 (AVA 1) fund, managed by Aquiti Gestion, aims to support entrepreneurs in the southwestern quarter of France. It backs startups from inception with the ambition of creating large-scale tech champions and promotes initiatives addressing current environmental and health challenges—contributing to a sustainable future for all regions. The fund is supported by many public and private institutional investors, including the National Seed Fund 3, managed by Bpifrance on behalf of the French State under the France 2030 plan, and the Nouvelle-Aquitaine Region through its investment vehicle Société Nouvelle-Aquitaine Participations.
About Newfund
Newfund is an early-stage VC fund supporting entrepreneurs driving breakthrough innovations across all sectors, with a strong focus on internationally ambitious projects. The fund invests in seed rounds to support the start of international expansion and provides long-term backing through follow-on investments. With a 25-person team based in Paris, Silicon Valley, and Nouvelle-Aquitaine, Newfund leverages proprietary technology tools and methods developed since its founding in 2008 by François Véron and Patrick Malka. Its portfolio includes over 120 innovative startups. Newfund brings together the largest base of entrepreneurs and family offices in France for an innovation-focused fund. Assets under management: €400 million.
